News

York raises funds to licence wound treatments

04 July 2008 12:44:00

Dermatology firm York Pharma has signed a licensing deal to market two leading wound infection treatments.

The company is paying Solvay Phamaceuticals BV €28.5m (£22.6m) for the current sales and world-wide commercial rights to Flammazine and Flammacerium, two treatments for wound infections.

The brands are currently on sale in 21 countries and produce revenues of about £8.5m a year, with France, Germany, Belgium and Spain the major markets. York plans to grow this revenue through promotional activity and securing authorisation to market the products in additional regions, including North America.

The acquisition will be funded by the proceeds of a £24.2m issue of senior secured non-convertible notes and subordinated convertible debentures.

The loan-note debt will be repayable over five years and carries a coupon of EURIBOR plus 11%, capped at 16%. The debentures have a coupon of 10% and are repayable over five years, either via cash or through the issue and allotment of new ordinary shares.

Further funding of £3.9m has been secured through the placing of 8.9m York shares at 44p each with institutional investors.

As part of the deal Solvay will be providing York with ready-to-sell versions of the product over a period of five years.

All data suppied by Digital Look (15 minute delay)




Risk Warning

There is an extra risk of losing money when shares are bought in some smaller companies including 'Penny Shares'. There is a big difference between the buying price and the selling price of these shares. If they have to be sold immediately, you may get back much less than you paid for them or you may have difficulty in selling them. Past performance is not a reliable indicator of future results. The price may change quickly and it may go down as well as up. You could lose every penny put into a particular share.

The information contained above has been compiled from documented sources which are believed to be reliable but, due to their very nature, are subject to a degree of historical inaccuracy and have not been independently verified and cannot be guaranteed. The pages on this website are provided for information only. City Equities Limited will not accept responsibility for loss incurred by any person or body acting, or refraining from acting, as a result of information and/or opinions given anywhere on this website. Issued by City Equities Limited, Aldermary House, 10-15 Queen Street, London, EC4N 1TY. Registered in England. Registered No. 2742847. Registered Address: Amwell House, 19 Amwell Street, Hoddeson, Herts. EN11 8TS. City Equities Limited is Authorised and regulated by the Financial Services Authority. Registration No. 155051.